Skip to main content
. 2018 May 18;111(1):69–77. doi: 10.1093/jnci/djy076

Table 3.

Multivariable Cox regression (No. of patients included in the model = 159, No. of patients with EFS event = 24)

Variable HR (95% CI) P*
Age: ≥50 vs <50 y 1.37 (0.60 to 3.13) .46
Histology grade: III vs I/II 1.21 (0.47 to 3.07) .70
Estrogen receptor: positive vs negative 0.72 (0.30 to 1.73) .46
Clinical stage: III vs II 1.89 (0.79 to 4.51) .15
Chemotherapy: anthracycline-based vs not 0.52 (0.22 to 1.22) .13
pCR: yes vs no 0.22 (0.08 to 0.61) .004
Baseline TILs (10-unit increase) 0.75 (0.56 to 1.00) .05
*

P values based on two-sided Wald tests from a multivariable Cox regression model including age, histology grade, estrogen receptor status, clinical stage, chemotherapy, pCR, and baseline TILs. CI= confidence interval; EFS = event-free survival; HR = hazard ratio; OR= odds ratio; pCR = pathologic complete response; TILs = tumor-infiltrating lymphocytes.